Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

Thyrotropin-producing pituitary adenoma associated with Graves' disease.

Koriyama N, Nakazaki M, Hashiguchi H, Aso K, Ikeda Y, Kimura T, Eto H, Hirano H, Nakano S, Tei C.

Eur J Endocrinol. 2004 Nov;151(5):587-94. Review.

2.

Thyrotropin-producing pituitary adenoma simultaneously existing with Graves' disease: a case report.

Arai N, Inaba M, Ichijyo T, Kagami H, Mine Y.

J Med Case Rep. 2017 Jan 6;11(1):9. doi: 10.1186/s13256-016-1172-4.

3.

Somatostatin receptor subtypes mRNA in TSH-secreting pituitary adenomas: a case showing a dramatic reduction in tumor size during short octreotide treatment.

Horiguchi K, Yamada M, Umezawa R, Satoh T, Hashimoto K, Tosaka M, Yamada S, Mori M.

Endocr J. 2007 Jun;54(3):371-8. Epub 2007 Apr 10.

4.

Short-term preoperative octreotide treatment for TSH-secreting pituitary adenoma.

Fukuhara N, Horiguchi K, Nishioka H, Suzuki H, Takeshita A, Takeuchi Y, Inoshita N, Yamada S.

Endocr J. 2015;62(1):21-7. doi: 10.1507/endocrj.EJ14-0118. Epub 2014 Oct 1.

5.

Preoperative long-acting octreotide treatment for invasive thyrotropin-secreting pituitary macroadenoma after previous radioiodine thyroid ablation.

Gruszka A, Zielinski GM, Kunert-Radek J.

J Clin Neurosci. 2014 Feb;21(2):340-2. doi: 10.1016/j.jocn.2013.02.038. Epub 2013 Aug 16.

PMID:
23958483
6.

Balance between somatostatin and D2 receptor expression drives TSH-secreting adenoma response to somatostatin analogues and dopastatins.

Gatto F, Barbieri F, Gatti M, Wurth R, Schulz S, Ravetti JL, Zona G, Culler MD, Saveanu A, Giusti M, Minuto F, Hofland LJ, Ferone D, Florio T.

Clin Endocrinol (Oxf). 2012 Mar;76(3):407-14. doi: 10.1111/j.1365-2265.2011.04200.x.

PMID:
21848909
7.

The thyroid "microsomal" antigen is an epitope on the thyrotropin receptor.

Islam N, Tuppal R, Hawe BS, Briones-Urbina R, Farid NR.

J Cell Biochem. 1986;31(2):107-20.

PMID:
2426288
8.
9.

In vivo and in vitro response to octreotide LAR in a TSH-secreting adenoma: characterization of somatostatin receptor expression and role of subtype 5.

Gatto F, Barbieri F, Castelletti L, Arvigo M, Pattarozzi A, Annunziata F, Saveanu A, Minuto F, Castellan L, Zona G, Florio T, Ferone D.

Pituitary. 2011 Jun;14(2):141-7. doi: 10.1007/s11102-010-0271-2.

PMID:
21086053
10.

Efficacy of the long-acting octreotide formulation (octreotide-LAR) in patients with thyrotropin-secreting pituitary adenomas.

Caron P, Arlot S, Bauters C, Chanson P, Kuhn JM, Pugeat M, Marechaud R, Teutsch C, Vidal E, Sassano P.

J Clin Endocrinol Metab. 2001 Jun;86(6):2849-53.

PMID:
11397898
11.

Expression of type 5 somatostatin receptor in TSH-secreting pituitary adenomas: a possible marker for predicting long-term response to octreotide therapy.

Yoshihara A, Isozaki O, Hizuka N, Nozoe Y, Harada C, Ono M, Kawamata T, Kubo O, Hori T, Takano K.

Endocr J. 2007 Feb;54(1):133-8. Epub 2006 Dec 11.

12.

Simultaneous assay for three types of thyrotropin receptor antibody activities using FRTL-5 cells in patients with autoimmune thyroid diseases.

Zhu Y, Portmann L, Dénéréaz N, Lemarchand-Béraud T.

Eur J Endocrinol. 1994 Oct;131(4):359-68.

PMID:
7921224
13.

A case of TSH-producing adenoma treated with octreotide in combination with thiamazole for the control of TSH and thyroid hormones after trans-sphenoidal neurosurgery.

Fukushima S, Takahashi M, Yoneda C, Matsuura H, Haruki T, Ogino J, Koike M, Kubo O, Kawamata T, Hashimoto N.

Endocr J. 2011;58(6):485-90. Epub 2011 Apr 26.

14.

Assays of TSH-receptor antibodies in 576 patients with various thyroid disorders: their incidence, significance and clinical usefulness.

Macchia E, Concetti R, Borgoni F, Cetani F, Fenzi GF, Pinchera A.

Autoimmunity. 1989;3(2):103-12.

PMID:
2577491
15.

Effect of octreotide acetate on thyrotropin-secreting adenoma: report of two cases and review of the literature.

Yoenem A, Cakyr B, Azal O, Corakcy A, Kutlu M, Oezata M.

Endocr Regul. 1999 Dec;33(4):169-74. Review.

PMID:
10700085
16.

Hashimoto's thyroiditis following Graves' disease.

Umar H, Muallima N, Adam JM, Sanusi H.

Acta Med Indones. 2010 Jan;42(1):31-5.

17.

[Octreotide in the diagnosis and treatment of pituitary thyrotropin-secreting adenoma].

Chen S, Li M, Lian XL, Zeng ZP, Dai WX, Li F, Yu W, Wang RZ.

Zhonghua Nei Ke Za Zhi. 2006 Nov;45(11):910-3. Chinese.

PMID:
17313878
18.

Thyroid fetal male microchimerisms in mothers with thyroid disorders: presence of Y-chromosomal immunofluorescence in thyroid-infiltrating lymphocytes is more prevalent in Hashimoto's thyroiditis and Graves' disease than in follicular adenomas.

Renné C, Ramos Lopez E, Steimle-Grauer SA, Ziolkowski P, Pani MA, Luther C, Holzer K, Encke A, Wahl RA, Bechstein WO, Usadel KH, Hansmann ML, Badenhoop K.

J Clin Endocrinol Metab. 2004 Nov;89(11):5810-4.

PMID:
15531546
19.

Thyrotropin secreting pituitary adenoma effectively treated with octreotide.

Fukuda T, Yokoyama N, Tamai M, Imaizumi M, Kimura H, Tominaga T, Ashizawa K, Kiriyama T, Yoshimine H, Ohishi K, Eguchi K.

Intern Med. 1998 Dec;37(12):1027-30.

20.

Treatment of thyrotropin-secreting pituitary adenomas with octreotide.

Shimatsu A, Murabe H, Kamoi K, Suzuki Y, Nakao K.

Endocr J. 1999 Feb;46(1):113-23.

Supplemental Content

Support Center